BCL6 and diffuse large B-cell lymphoma: Certain biomarkers have been assessed to determine their relationship with survival outcomes in DLBCL patients treated with a dose-adjusted R-EPOCH regimen, such as bcl-2, bcl-6, and the GCB subtype [33, 35, 37].